Hologic (NASDAQ:HOLX) Downgraded by Wall Street Zen to "Hold"

Key Points

• Hologic has been downgraded from a "buy" to a "hold" rating by Wall Street Zen in a recent report.
• Despite the downgrade, several analysts maintain positive views with Hologic receiving an average "Moderate Buy" rating and a price target of $78.00.
• Hologic reported earnings of $1.08 per share for the last quarter, surpassing expectations, with revenue increasing by 1.2% year-over-year.

Hologic (NASDAQ:HOLX - Get Free Report) was downgraded by analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a research note issued on Monday.

Other equities research analysts have also issued research reports about the company. Argus raised Hologic from a "hold" rating to a "buy" rating and set a $80.00 target price on the stock in a research report on Monday, August 18th. Evercore ISI lifted their target price on Hologic from $62.00 to $68.00 and gave the company an "in-line" rating in a research report on Tuesday, July 8th. Citigroup raised Hologic from a "neutral" rating to a "buy" rating and lifted their target price for the company from $60.00 to $80.00 in a research report on Wednesday, July 9th. Morgan Stanley lifted their target price on Hologic from $65.00 to $69.00 and gave the company an "equal weight" rating in a research report on Thursday, July 31st. Finally, Royal Bank Of Canada raised Hologic from a "sector perform" rating to an "outperform" rating and lifted their target price for the company from $72.00 to $87.00 in a research report on Wednesday, August 6th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and eight have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $79.38.

Hologic Stock Down 2.8%

Shares of NASDAQ HOLX traded down $1.94 during mid-day trading on Monday, reaching $66.33. 8,515,121 shares of the company's stock were exchanged, compared to its average volume of 1,762,988. The firm has a market capitalization of $14.75 billion, a price-to-earnings ratio of 27.52, a PEG ratio of 2.47 and a beta of 0.57. The company has a current ratio of 3.55, a quick ratio of 2.81 and a debt-to-equity ratio of 0.52. The business has a fifty day simple moving average of $66.47 and a 200 day simple moving average of $62.75. Hologic has a twelve month low of $51.90 and a twelve month high of $84.39.

Hologic (NASDAQ:HOLX - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 EPS for the quarter, topping analysts' consensus estimates of $1.05 by $0.03. The company had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. Hologic had a return on equity of 19.69% and a net margin of 13.79%.Hologic's revenue was up 1.2% compared to the same quarter last year. During the same quarter last year, the firm posted $1.06 earnings per share. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. As a group, equities analysts expect that Hologic will post 4.28 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Capital Investment Counsel Inc grew its stake in shares of Hologic by 2.6% in the second quarter. Capital Investment Counsel Inc now owns 5,814 shares of the medical equipment provider's stock worth $379,000 after purchasing an additional 150 shares during the last quarter. Greenleaf Trust grew its stake in shares of Hologic by 5.1% in the second quarter. Greenleaf Trust now owns 3,579 shares of the medical equipment provider's stock worth $233,000 after purchasing an additional 173 shares during the last quarter. Beverly Hills Private Wealth LLC grew its stake in shares of Hologic by 3.6% in the first quarter. Beverly Hills Private Wealth LLC now owns 5,173 shares of the medical equipment provider's stock worth $320,000 after purchasing an additional 180 shares during the last quarter. Schroder Investment Management Group grew its stake in shares of Hologic by 1.4% in the second quarter. Schroder Investment Management Group now owns 15,758 shares of the medical equipment provider's stock worth $1,027,000 after purchasing an additional 210 shares during the last quarter. Finally, Allworth Financial LP grew its stake in shares of Hologic by 46.0% in the first quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider's stock worth $40,000 after purchasing an additional 216 shares during the last quarter. 94.73% of the stock is currently owned by institutional investors.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.